Nicox Biotech Stock Jumps Over 7% Following Regulatory Green Light in China
The biotech company from Biot (Alpes-Maritimes) sees a significant uptick in mid-morning trading on the Paris Stock Exchange. The stock is reacting to a major regulatory breakthrough achieved by its Chinese partner for the antiglaucoma eye drops, its flagship asset. The session is part of a generally rising Parisian market.
Chinese Regulator's Approval Propels Stock Towards €0.51 Resistance
Nicox's stock has risen 6.23% to €0.3920, buoyed by the favorable opinion from the Chinese Center for Drug Evaluation (CDE) obtained by Ocumension Therapeutics on NCX 470. The exclusive partner of the biotech in the Chinese market can now file for market authorization for this eye drop intended for the treatment of glaucoma, as detailed in the press release published this Thursday. This regulatory step potentially paves the way for commercialization in China.
The rebound of the day brings the weekly performance to nearly 11%, after a decline of 7.2% over three months. The annual increase now exceeds 74%, reflecting the gradual improvement of the stock since last summer.
Above All Its Moving Averages, The Stock Aims for the €0.51 Resistance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The session's surge has pushed the price above the three moving averages monitored by traders, with a gap of nearly 6% over the MM20 (€0.37) and the MM200 (€0.37), while the MM50 (€0.39) has just been surpassed. The RSI at 44 remains in the neutral zone, leaving room before reaching an overbought configuration, while the next technical high is at €0.51. The support at €0.35, tested several times in recent months, serves as a reference floor.
On the agenda, the ordinary and extraordinary general meeting is scheduled for June 24, 2026. The commercial realization of NCX 470 in China will depend on the timeline for the review of the file by health authorities.
Nicox a significativement renforcé sa position financière en 2025.
Risks mentioned
Baisse potentielle de la demande pour les nouveaux produits.
Risque de retard dans les soumissions réglementaires.
Opportunities identified
Soumission prévue de la NDA de NCX 470 aux États-Unis en été 2026.
Initiation du programme clinique de phase 3 pour NCX 470 au Japon.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
